IV 
110TH CONGRESS 
2D SESSION 
H. CON. RES. 342 
Expressing the sense of Congress that the Food and Drug Administration’s 
(FDA) new policy restricting women’s access to medications containing 
estriol does not serve the public interest. 
IN THE HOUSE OF REPRESENTATIVES 
MAY 6, 2008 
Mr. ROSS (for himself, Mrs. EMERSON, Ms. BALDWIN, Mr. BURGESS, Mr. 
FARR, Mr. CARTER, and Ms. GIFFORDS) submitted the following concur-
rent resolution; which was referred to the Committee on Energy and 
Commerce 
CONCURRENT RESOLUTION 
Expressing the sense of Congress that the Food and Drug 
Administration’s (FDA) new policy restricting women’s 
access to medications containing estriol does not serve 
the public interest. 
Whereas menopause is often a challenging transition for mil-
lions of women that requires specialized medications and 
medical treatments; 
Whereas physicians prescribe a variety of pharmaceutical 
treatment options to treat women experiencing the symp-
toms of menopause; 
Whereas individual women respond differently to different 
treatment options; 
VerDate Aug 31 2005 
02:14 May 07, 2008
Jkt 069200
PO 00000
Frm 00001
Fmt 6652
Sfmt 6300
E:\BILLS\HC342.IH
HC342
jbell on PROD1PC69 with BILLS
•HCON 342 IH 
Whereas women’s physicians determine on a case-by-case 
basis which treatment option is optimal for each woman; 
Whereas many physicians prescribe compounded estrogen and 
other bioidentical hormone treatments for patients for a 
variety of reasons; 
Whereas many physicians prescribe compounded estrogen 
treatments that contain estriol to treat menopausal and 
perimenopausal women; 
Whereas estriol is one of three estrogens produced by the 
human body; 
Whereas estriol has been prescribed and used for decades in 
the United States; 
Whereas Congress has long recognized active pharmaceutical 
ingredients meeting standards set by the United States 
Pharmacopeia as permissible options for physician pre-
scribing and pharmacy compounding; 
Whereas the Food and Drug Administration (FDA) has an-
nounced that it will no longer permit compounding phar-
macists to prepare medications containing estriol pursu-
ant to a doctor’s prescription; 
Whereas insurers are now denying women reimbursement for 
compounded medications containing estriol as a result of 
the FDA’s announcement; and 
Whereas the FDA has acknowledged that it is unaware of 
any adverse events associated with use of compounded 
medications containing estriol: Now, therefore, be it 
Resolved by the House of Representatives (the Senate 
concurring), That it is the sense of the Congress that— 
VerDate Aug 31 2005 
02:14 May 07, 2008
Jkt 069200
PO 00000
Frm 00002
Fmt 6652
Sfmt 6201
E:\BILLS\HC342.IH
HC342
jbell on PROD1PC69 with BILLS
•HCON 342 IH 
(1) physicians are in the best position to deter-
mine which medications are most appropriate for 
their patients; 
(2) the Food and Drug Administration (FDA) 
should respect the physician-patient relationship; 
and 
(3) the FDA should reverse its policy that aims 
to eliminate patients’ access to compounded medica-
tions containing estriol that their physicians pre-
scribe for them. 
Æ 
VerDate Aug 31 2005 
02:14 May 07, 2008
Jkt 069200
PO 00000
Frm 00003
Fmt 6652
Sfmt 6301
E:\BILLS\HC342.IH
HC342
jbell on PROD1PC69 with BILLS